Enrollment Criteria (Adult)

Patient ID __ __ - __ **ID** __ - __ __ __

Date of Determination: **ERLDATE**

Check if rescreen: ☐ **RSC**

SECTION I: INCLUSION CRITERIA

1. Enrolled in the HBRN Cohort Study or completed the necessary components of the Cohort baseline evaluation by the end of the baseline visit for this trial. **INCOHORT**	☐ Yes	☐ No
2. Patient is ≥ 18 years of age at the baseline visit (day 0) **INAGEIT** Patients > 50 years of age at baseline visit will need to have a liver biopsy as standard of care with HAI ≤ 3 and Ishak fibrosis score ≤ 1 within 96 weeks prior baseline visit. **AGE50** ☐ Patient >50 year of age: Biopsy:HAI **HAIAGE** Ishak score **ISHAKAGE** **BIOPAM/D/Y** *(mm/dd/yy)*	☐ Yes	☐ No
3. Documented chronic HBV infection as evidenced by detection of HBsAg in serum for ≥ 24 weeks prior to baseline visit **OR** at least one positive HBsAg and negative anti-HBc IgM within 24 weeks prior to baseline visit **OR** at least one positive HBsAg and two positive HBV DNA over a period of ≥ 24 weeks prior to baseline visit. **INCHB**	☐ Yes	☐ No
4. Presence of HBeAg in serum at the last screening visit within 6 weeks of baseline visit. **INHBE**	☐ Yes	☐ No
5. Serum HBV DNA >10^7 IU/mL on at least 2 occasions drawn at least 12 weeks apart during the 52 weeks before baseline visit. One of the HBV DNA levels must be within the 6 weeks prior to the baseline visit. **INDNA** HBV DNA results: Level (IU/mL) Date *(mm/dd/yy)* Lower limit of detection **__BDNA1__** **BDNA1M/D/Y** **__BDNALL1__** **__BDNA2__** **BDNA2M/D/Y** **__BDNALL2__**	☐ Yes	☐ No
6. ALT levels persistently ≤ 45 IU/L for males and ≤ 30 IU/L for females (approximately 1.5 times the upper limit of the normal range) as documented by at least three measurements: one taken 28-52 weeks before baseline visit; one taken 6-28 weeks before baseline visit; and the final value within 6 weeks prior to the baseline visit. **INALT** ALT result 28-52 weeks prior: **ALT48** IU/L **ALT48M/D/Y** *(mm/dd/yy)* ALT result 6-28 weeks prior: **ALT24** IU/L **ALT24M/D/Y** *(mm/dd/yy)* ALT result within 6 weeks: **ALT6** IU/L **ALT6M/D/Y** *(mm/dd/yy)*	☐ Yes	☐ No
7. No evidence of HCC based upon AFP≤ 20ng/mL at screening visit (up to 6 weeks prior to baseline visit): **NOHCC** a) Participants who meet AASLD criteria for HCC surveillance must have negative liver imaging as shown by US, CT or MRI within 28 weeks prior to the baseline visit as part of standard of care. Imaging within 28 weeks **IMAGM/D/Y** *(mm/dd/yy)* b) Participants with AFP > 20 ng/mL must be evaluated clinically with additional imaging and shown not to have HCC on CT or MRI before they can be enrolled.	☐ Yes	☐ No
8. Patient has provided written informed consent and agrees to adhere to study requirements **ITCONS**	☐ Yes	☐ No

SECTION II: EXCLUSION CRITERIA

1. Any history of hepatic decompensation, including but not limited to ascites, variceal bleeding, or hepatic encephalopathy **ITHDC**	☐ Yes	☐ No
2. Evidence of decompensated liver disease prior to or during screening, including direct bilirubin >0.5 mg/dL, INR >1.5, serum albumin <3.5 g/dL **DECOMP**	☐ Yes	☐ No
3. Platelet count <120,000/mm^3, hemoglobin <13 g/dL (males) or <12 g/dL (females), ANC <1500/mm^3 (<1000/mm^3 for African Americans) at the last screening visit **EXLAB**	☐ Yes	☐ No
4. Previous treatment with medications that have established activity against HBV including but not limited to interferon and nucleos(t)ide analogs ≥ 24 weeks. Patients with < 24 weeks of prior HBV treatment and a wash-out period >24 weeks are not excluded. Brief and episodic use of famciclovir or valacyclovir for herpes infection is not exclusionary. **TXNAIVE**	☐ Yes	☐ No
5. Known allergy or intolerance to the study medications **EXALGY**	☐ Yes	☐ No
6. Female patient who is pregnant or breastfeeding **EXPREG**	☐ Yes	☐ No or N/A

7. Female patient of childbearing potential unable or unwilling to use a reliable method of contraception during treatment **EXCONT** ☐ check if patient not of child bearing potential **NOCHILD**	☐ Yes	☐ No or N/A
8. Renal insufficiency with calculated creatinine clearance < 50 mL/min at last screening visit **EXRENAL**	☐ Yes	☐ No
9. History of alcohol or drug abuse within 48 weeks of baseline visit **EXALC**	☐ Yes	☐ No
10. Previous liver or other organ transplantation including engrafted bone marrow transplant **EXTX**	☐ Yes	☐ No
11. Any other concomitant liver disease, including but not limited to hepatitis C or D. Non-alcoholic fatty liver disease (NAFLD) with steatosis and/or mild to moderate steatohepatitis is acceptable but NALFD with severe steatohepatitis is exclusionary. **OTHLVDX**	☐ Yes	☐ No
12. Presence of anti-HDV or anti-HCV (unless HCV RNA negative) in serum on any occasion in the 144 weeks prior to baseline visit **OTHVIRDX**	☐ Yes	☐ No
13. Presence of anti-HIV (test to be completed within the 6 weeks prior to baseline visit) **EXHIV**	☐ Yes	☐ No
14. Pre-existing psychiatric condition(s) including but not limited to: **EXPSY** a) Current moderate or severe depression as determined by the study physician b) History of depression requiring hospitalization within the past 10 years c) History of suicidal or homicidal attempt within the past 10 years d) History of severe psychiatric disorders including but not limited to schizophrenia, psychosis, or bipolar disorder, as determined by a study physician.	☐ Yes	☐ No
15. History of immune-mediated or cerebrovascular disease, chronic pulmonary or cardiac disease associated with functional limitation, retinopathy, uncontrolled thyroid disease, poorly controlled diabetes or uncontrolled seizure disorder, as determined by the study physician **OTHDX**	☐ Yes	☐ No
16. Any medical condition requiring or likely to require chronic systemic administration of corticosteroids or other immunosuppressive medications during the course of the study **IMMTX**	☐ Yes	☐ No
17. Evidence of active or suspected malignancy, or a history of malignancy within the last 144 weeks prior to baseline visit (except adequately treated carcinoma in situ or basal cell carcinoma of the skin) **EXCANC**	☐ Yes	☐ No
18. Expected need for ongoing use of any antivirals with activity against HBV during the course of the study **ANTIVTX**	☐ Yes	☐ No
19. Concomitant use of complementary or alternative medications purported to have antiviral activity **HERBAL**	☐ Yes	☐ No
20. Participation in any other clinical trial involving investigational drugs within 30 days of baseline visit or intention to participate in another clinical trial involving investigational drugs during participation in this study **INVRX2**	☐ Yes	☐ No
21. Any medical condition that would, in the opinion of the study physician, be predicted to be exacerbated by therapy or that would limit study participation **EXDXPI**	☐ Yes	☐ No
22. Any other condition or situation that, in the opinion of the study physician, would make the patient unsuitable for enrollment or could interfere with the patient participating in and completing the study? **PIOTH** If Yes, specify _____ **PIOTHS** _____	☐ Yes	☐ No

If the responses to all inclusion criteria are YES and all exclusion criteria are NO, the patient is eligible to participate in the Immune Tolerant Trial.

Is the patient eligible to participate in the Immune Tolerant trial? ☐ Yes ☐ No **ENROLLIT**

Investigator signature: _____

Data collector initials: **DCID**

Date data collection completed *(mm/dd/yy)*: **DCM** / **DCD** / **DCY**